Results 61 to 70 of about 11,617 (148)

Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks

Indian Journal of Ophthalmology, 2015
In this study, we reported the clinical results of switching from ranibizumab to aflibercept for the treatment of an insufficient responder with choroidal neovascularization (CNV) secondary to angioid streaks (AS).
Ebru Esen, Selçuk Sizmaz, Nihal Demircan   +2 more
doaj   +1 more source

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration

Clinical Ophthalmology, 2018
Claudia Taipale,1,2 Ilkka Laine,1,3 Raimo Tuuminen1,3 1Helsinki Retina Research Group, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 2Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 3Department of
Taipale C, Laine I, Tuuminen R
doaj  

Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study

American Journal of Ophthalmology Case Reports
Purpose: To compare the safety and efficacy of aflibercept with brolucizumab for recalcitrant diabetic macular edema (DME). Observations: At week 52, no significant visual improvement was noted in the eyes treated with either brolucizumab (P = 0.527) or ...
Debdulal Chakraborty, Ashish Sharma, Soumen Mondal, Jay Sheth, Tushar Kanti Sinha, Subhendu Boral, Angshuman Mukherjee, Ranabir Bhattacharya, Ritobroto Maitra   +8 more
doaj   +1 more source

Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration

Therapeutic Advances in Ophthalmology
What is this summary about? • This is a summary of a publication about the PULSAR study, which was published in The Lancet scientific journal. • Wet age-related macular degeneration (or AMD) is a long-term eye disease in which abnormal blood vessels grow
Paolo Lanzetta, Jean-François Korobelnik, Jeffrey S. Heier, Sergio Leal, Frank G. Holz, William Lloyd Clark, David Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J. Berliner, Andrea Schulze, Thomas Schmelter, Ursula Schmidt-Ott, Xin Zhang, Robert Vitti, Karen W. Chu, Kimberly Reed, Rohini Rao, Rafia Bhore, Yenchieh Cheng, Tien Y. Wong   +20 more
doaj   +1 more source

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?

Life
Purpose: To describe the indication spectrum for high-dose 8 mg aflibercept for neovascular age-related macular degeneration (nAMD) in a real-world cohort in a tertiary referral center.
Caspar Liesenhoff, Carolin Meyrl, Daniel Krause, Franziska Eckardt, Anna Lorger, Viktoria Deiters, Johannes Schiefelbein, Julian Elias Klaas, Benedikt Schworm, Siegfried G. Priglinger, Jakob Siedlecki   +10 more
doaj   +1 more source

Switching to faricimab from aflibercept during maintenance treatment period for age-related macular degeneration

Scientific Reports
To compare the short-term treatment outcomes of aflibercept and faricimab for neovascular age-related macular degeneration (nAMD) during the maintenance treatment period, we included 82 eyes of 74 patients who switched from aflibercept to faricimab ...
Misa Masaoka, Kenji Yamashiro
doaj   +1 more source

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy

Pharmaceuticals
Purpose: The aim was to compare the short-term outcomes of aflibercept 8 mg and brolucizumab for the treatment of polypoidal choroidal vasculopathy (PCV). Methods: This study included 48 eyes of 48 patients with PCV.
Yoshiko Fukuda, Yoichi Sakurada, Yumi Kotoda, Misa Kimura, Kenji Kashiwagi   +4 more
doaj   +1 more source

Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance

Clinical Ophthalmology, 2018
Ali Dirani, Irmela Mantel Department of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland Purpose: To investigate whether tolerance to the anti-VEGF drug, ranibizumab, develops after ...
Dirani A, Mantel I
doaj  

Eye Drop Development of Anti-VEGF Therapeutics by Ocular Penetrating Carrier to the Posterior Region of the Eye. [PDF]

Transl Vis Sci Technol
Chiueh VC, Lee LL, Tau S, Luu M, Park JH, Lee T.   +5 more
europepmc   +1 more source

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

Clinical Ophthalmology
Hazem Saleh Aljuhani,1,* Rahaf A Hubayni,2,3,* Jumanah Qedair,2,3 Ziad M Bukhari,4 Ahmed Alzahrani,4 Razan Osama Bawazir,2,3 Orjwan Salah Badghaish,2,3 Faisal Alqahtani5 1Ophthalmology Department, Jeddah Eye Hospital, Jeddah, Saudi Arabia;
Aljuhani HS, Hubayni RA, Qedair J, Bukhari ZM, Alzahrani A, Bawazir RO, Badghaish OS, Alqahtani F   +7 more
doaj